Search
ISB 1342
go.drugbank.com/drugs/DB17251InvestigationalISB 1342 is a bispecific antibody simultaneously targeting CD38 and CD3.
TBX-1400
go.drugbank.com/drugs/DB18263InvestigationalTBX-1400 consists of human donor hematopoietic stem and progenitor cells.
Sipagladenant
go.drugbank.com/drugs/DB17080InvestigationalKW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]
Vamotinib
go.drugbank.com/drugs/DB15396InvestigationalVamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).
Clocapramine
go.drugbank.com/drugs/DB09003ExperimentalIn addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. … Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia.
Transcrocetinate
go.drugbank.com/drugs/DB05974InvestigationalVitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Sepantronium
go.drugbank.com/drugs/DB17062InvestigationalSepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.[A253167]
Pralurbactam
go.drugbank.com/drugs/DB19437InvestigationalPralurbactam is under investigation in clinical trial NCT06633718 (Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI).
Linopristin
go.drugbank.com/drugs/DB19296ExperimentalThe combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections. … Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with [Virginiamycin M1].
Rintodestrant
go.drugbank.com/drugs/DB21472InvestigationalRintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).